Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AbCellera Biologics Inc. (ABCL : NSDQ)

• Company Description    AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada. Number of Employees: 596

• Price / Volume Information    Yesterday's Closing Price: $3.61 Daily Weekly Monthly 20 Day Moving Average: 4,281,565 shares Shares Outstanding: 303.16 (millions) Market Capitalization: $1,094.41 (millions) Beta: 0.81 52 Week High: $6.52 52 Week Low: $1.89 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.48% -5.25% 12 Week -1.10% -1.41% Year To Date 5.56% 4.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 150 W 4TH AVENUE - VANCOUVER,A1 V5Y 1G6 CAN ph: 604-559-9005 fax: - ir@abcellera.com http://www.abcellera.com

• General Corporate Information    Officers Carl L. G. Hansen - Chief Executive Officer and Director Andrew Booth - Chief Financial Officer Stephen R. Quake - Director Michael Hayden - Director John S. Montalbano - Director Peer Information AbCellera Biologics Inc. (CORR.) AbCellera Biologics Inc. (RSPI) AbCellera Biologics Inc. (CGXP) AbCellera Biologics Inc. (BGEN) AbCellera Biologics Inc. (GTBP) AbCellera Biologics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00288U106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/14/26 Share - Related Items Shares Outstanding: 303.16 Most Recent Split Date: (:1) Beta: 0.81 Market Capitalization: $1,094.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.13 Price/Cash Flow: - Price / Sales: 14.57 EPS Growth vs. Year Ago Period: 72.73% vs. Previous Quarter: 84.21% Sales Growth vs. Year Ago Period: 788.18% vs. Previous Quarter: 400.87% ROE 12/31/25 - -15.05 09/30/25 - -17.21 06/30/25 - -16.17 ROA 12/31/25 - -10.92 09/30/25 - -12.76 06/30/25 - -12.24 Current Ratio 12/31/25 - 11.32 09/30/25 - 10.10 06/30/25 - 11.07 Quick Ratio 12/31/25 - - 09/30/25 - 10.10 06/30/25 - 11.07 Operating Margin 12/31/25 - -198.37 09/30/25 - -493.42 06/30/25 - -511.88 Net Margin 12/31/25 - -198.37 09/30/25 - -493.42 06/30/25 - -511.88 Pre-Tax Margin 12/31/25 - -236.39 09/30/25 - -580.13 06/30/25 - -604.66 Book Value 12/31/25 - 3.19 09/30/25 - 3.23 06/30/25 - 3.37 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©